Aquestive Therapeutics, Inc.
AQST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $58 | $51 | $48 | $51 |
| % Growth | 13.8% | 6.1% | -6.2% | – |
| Cost of Goods Sold | $18 | $21 | $19 | $15 |
| Gross Profit | $40 | $30 | $28 | $36 |
| % Margin | 69% | 58.8% | 59.3% | 70.5% |
| R&D Expenses | $20 | $13 | $17 | $17 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $50 | $32 | $53 | $53 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $70 | $45 | $70 | $71 |
| Operating Income | -$31 | -$15 | -$42 | -$35 |
| % Margin | -53.5% | -29.9% | -88.2% | -68.2% |
| Other Income/Exp. Net | -$13 | $7 | -$12 | -$36 |
| Pre-Tax Income | -$44 | -$8 | -$54 | -$71 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$44 | -$8 | -$54 | -$71 |
| % Margin | -76.7% | -15.6% | -114.1% | -138.8% |
| EPS | -0.51 | -0.13 | -1.12 | -1.85 |
| % Growth | -292.3% | 88.4% | 39.5% | – |
| EPS Diluted | -0.51 | -0.13 | -1.12 | -1.85 |
| Weighted Avg Shares Out | 87 | 61 | 49 | 38 |
| Weighted Avg Shares Out Dil | 87 | 61 | 49 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $16 | $0 | $0 |
| Interest Expense | $17 | $7 | $12 | $22 |
| Depreciation & Amortization | $1 | $1 | $2 | $3 |
| EBITDA | -$27 | $1 | -$40 | -$45 |
| % Margin | -46.2% | 2.3% | -83% | -88.8% |